{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 63a24628-8168-4a6f-9c05-034ba9515938 --><h2>Prevalence</h2><!-- end field 63a24628-8168-4a6f-9c05-034ba9515938 -->","summary":"","htmlStringContent":"<!-- begin item 72077628-3dfd-4380-ae0c-2a7996fbe28f --><!-- end item 72077628-3dfd-4380-ae0c-2a7996fbe28f -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"12c34218-7b6c-5df0-8c2b-dcb026b56010","slug":"prevalence-of-cervical-cancer","fullItemName":"Prevalence of cervical cancer","depth":3,"htmlHeader":"<!-- begin field c3a12a4d-5d0f-403b-b0d7-89ccb56c9664 --><h3>What is the prevalence of cervical cancer?</h3><!-- end field c3a12a4d-5d0f-403b-b0d7-89ccb56c9664 -->","summary":null,"htmlStringContent":"<!-- begin item 8a8e9b93-119a-4ebc-a72a-f4570e48f214 --><!-- begin field 04e0bee0-0649-4e9b-8644-dec40641bca1 --><ul><li><strong>Pre-invasive lesions. </strong><ul><li>In 2014 there were 31,829 new registrations of cervical intraepithelial neoplasia 3 (CIN 3) in the UK. Most of these (54%) were in women younger than 30 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Cancer Research UK, 2016c</a>].</li></ul></li><li><strong>Invasive cancer of the cervix. </strong><ul><li>In 2014, there were 3,224 new diagnoses of invasive cancer of the cervix in the UK. Invasive cancer of the cervix is the thirteenth most common cancer in women in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Cancer Research UK, 2016c</a>].</li><li>It has been estimated that the lifetime risk in the UK of developing cervical cancer is 1 in 135 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Cancer Research UK, 2016c</a>].</li><li>The annual incidence of cervical cancer per 100,000 women by age group in England is [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>]:<ul><li>Aged 20–24 years: 2.6.</li><li>Aged 25–34 years: 11.7.</li><li>Aged 35–44 years: 4.8.</li><li>Aged 45–54 years: 3.4.</li></ul></li><li>Cervical cancer accounts for 8% of cancers diagnosed in women worldwide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Cancer Research UK, 2016c</a>].</li></ul></li></ul><!-- end field 04e0bee0-0649-4e9b-8644-dec40641bca1 --><!-- end item 8a8e9b93-119a-4ebc-a72a-f4570e48f214 -->","subChapters":[]},{"id":"d0b0dd61-2f39-542d-9cef-f1719739f997","slug":"prevalence-of-hpv-infection","fullItemName":"Prevalence of HPV infection","depth":3,"htmlHeader":"<!-- begin field effc6e55-ba6f-4fb0-baa9-f0dec6582ecb --><h3>What is the prevalence of human papillomavirus (HPV) infection?</h3><!-- end field effc6e55-ba6f-4fb0-baa9-f0dec6582ecb -->","summary":null,"htmlStringContent":"<!-- begin item feba5c44-257f-4cd2-bf29-20ba56bd00d1 --><!-- begin field 258c22da-0dee-4d0e-bad3-df2cf659252a --><ul><li>Around 50–79% of sexually active women have a lifetime risk of being infected with human papillomavirus (HPV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Cadman, 2006</a>].</li><li>Almost 40% of women are infected with HPV within two years of first sexual activity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>].</li><li>Prevalence is extremely low (5%) in girls younger than 14 years of age, but rises in the mid-teens until the mid 20s where prevalence is 40% in those aged 20–24 years. Thereafter it declines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Kitchener et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Jit et al, 2007</a>].<ul><li>The most common infection is with type 16 (12%) which is oncogenic.</li><li>Being seropositive for types 6, 11, and 18 is associated with being seropositive for type 16.</li></ul></li><li>The prevalence of high-risk HPV is 16% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Howell-Jones et al, 2010</a>].</li></ul><!-- end field 258c22da-0dee-4d0e-bad3-df2cf659252a --><!-- end item feba5c44-257f-4cd2-bf29-20ba56bd00d1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}